From empiric to mechanism-based therapy for peripheral T cell lymphoma
نویسندگان
چکیده
منابع مشابه
Peripheral T-cell Lymphoma of the Uvula: A Rare Entity
Abstract Introduction: Extra-nodal exposition of T-cell non-hodgkin lymphoma (NHL) is extremely rare, and is frequently observed in patients with immune system dysfunction. Peripheral T-cell lymphoma does not express CD56 is rare. Malignant lymphoma of the uvula is exceedingly unusual. The current study reported a case of peripheral T-cell lymphoma of the uvula in an immunecompetent patient. ...
متن کاملPeripheral T-cell Lymphoma of the Uvula: A Rare Entity
Abstract Introduction: Extra-nodal exposition of T-cell non-hodgkin lymphoma (NHL) is extremely rare, and is frequently observed in patients with immune system dysfunction. Peripheral T-cell lymphoma does not express CD56 is rare. Malignant lymphoma of the uvula is exceedingly unusual. The current study reported a case of peripheral T-cell lymphoma of the uvula in an immunecompetent patient. ...
متن کاملPeripheral T-cell lymphoma.
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is...
متن کاملHigh-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Peripheral T/NK-cell lymphomas (PTCL) comprise a rare and heterogeneous group of malignancies accounting for approximately 10-15% of all nonHodgkin’s lymphomas (NHL) in Western countries. PTCL in general are characterized by an aggressive course and most studies revealed the T-cell phenotype as a negative prognostic marker. The international prognostic index (IPI) and T-cell specific prognostic...
متن کاملTherapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
BACKGROUND Gemcitabine is a novel nucleoside analogue which has shown promising results in most solid tumors; like the arabinosylcytosine analogue, gemcitabine may be an active drug in lymphoproliferative malignancies. We tested it in pretreated peripheral T-cell lymphoma patients with isolated skin involvement. PATIENTS AND METHODS We performed a phase II study with the drug in 13 pretreated...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Hematology
سال: 2014
ISSN: 0925-5710,1865-3774
DOI: 10.1007/s12185-014-1521-2